Stock Code: 000028/200028 Notice No.: 2018-35
Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
Summary of Semi-Annual Report 2018
I. Important Notice
The summary is abstract from full-text of annual report, for more details of operating results, financial condition and future
development plan of the Company; investors should found in the full-text of annual report that published on media appointed by
CSRC.
No objection statement of directors, supervisors and senior executives
Whole directors attended the Meeting in person for Report deliberation
Prompt of modified auditing opinion
□ Applicable √ Not applicable
Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting
period
□ Applicable √ Not applicable
The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reserves
Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period
□ Applicable √ Not applicable
II. Basic information of the company
1. Company profile
Short form of the stock Sinopharm Accord, Accord B Stock code 000028, 200028
Stock exchange for listing Shenzhen Stock Exchange
Person/Way to contact Secretary of the Board Rep. of security affairs
Name Chen Changbing Wang Zhaoyu
Accord Pharm. Bldg., No. 15, Ba Gua Si
Accord Pharm. Bldg., No. 15, Ba Gua Si
Office add. Road, Futian District, Shenzhen, Guangdong Road, Futian District, Shenzhen, Guangdong
Province Province
Tel. +(86)755 25875195 +(86)755 25875222
E-mail gyyzinvestor@sinopharm.com gyyz0028@sinopharm.com
2. Main financial data and index
Whether it has retroactive adjustment or re-statement on previous accounting data
□Yes √No
Increase/decrease in this
Current Period Same period of last year
report y-o-y
1
Operating income (RMB) 20,779,166,699.67 20,524,807,669.57 1.24%
Net profit attributable to shareholders of
641,727,034.93 556,125,318.19 15.39%
the listed company(RMB)
Net profit attributable to shareholders of
the listed company after deducting 623,296,339.34 546,253,390.00 14.10%
non-recurring gains and losses(RMB)
Net cash flow arising from operating
225,357,709.20 228,337,431.40 -1.30%
activities(RMB)
Basic earnings per share (RMB/Share) 1.50 1.30 15.38%
Diluted earnings per share (RMB/Share) 1.50 1.30 15.38%
Weighted average ROE 6.62% 6.41% 0.21%
Increase/decrease in this
End of current period End of last period report-end over that of last
period-end
Total assets (RMB) 24,013,015,677.32 22,343,643,527.77 7.47%
Net assets attributable to shareholder of
9,910,258,628.12 9,396,572,345.88 5.47%
listed company (RMB)
3. Number of shareholders and share-holding
In Share
Total preference shareholders
Total common shareholders at with voting rights recovered at
19,539 0
period-end end of reporting period (if
applicable)
Top ten shareholders
Proportion Shares pledged/frozen
Nature of Amount of
Full name of Shareholders of shares Amount of restricted shares held
shareholder shares held State of share Amount
held
Sinopharm Group Co., State-owned
56.06% 239,999,991 55,057,700
Ltd corporate
HTHK/CMG
FSGUFP-CMG FIRST Overseas
2.37% 10,141,182 0
STATE CHINA corporate
GROWTH FD
China Life Insurance Co., Domestic
Ltd. – tradition –general non
2.02% 8,654,592 0
insurance products state-owned
-005L-CT001 Shen corporate
China United Property Domestic
1.42% 6,092,905 0
Insurance Company non
2
Limited – Traditional state-owned
Insurance Products corporate
China National
State-owned
Pharmaceutical Foreign 1.24% 5,323,043 5,323,043
corporate
Trade Corp.
GUOTAI JUNAN
Overseas
SECURITIES(HONGKO 1.19% 5,086,260 0
corporate
NG) LIMITED
New China Life Insurance Domestic
Co., Ltd. – Bonus – non
0.98% 4,199,772 0
Individual bonuses - state-owned
-018L-FH002 Shen corporate
# Beijing Haoqing
Domestic
Fortune Investment
non
Management Co., Ltd. – 0.96% 4,118,716 0
state-owned
Haoqing Value Stable
corporate
No.8 Investment Fund
UBS AG LONDON Overseas
0.89% 3,818,884 0
BRANCH corporate
Central Huijin Investment State-owned
0.89% 3,804,400 0
Ltd. corporate
Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade
Corporation have the same actual controller, which is China National Pharmaceutical
Explanation on associated relationship Group Corporation. It is unknown that there exists no associated relationship or belongs to
among the aforesaid shareholders the consistent actionist among the other tradable shareholders regulated by the
Management Measure of Information Disclosure on Change of Shareholding for Listed
Companies.
Explanation on shareholders involving
Beijing Haoqing Fortune Investment Management Co., Ltd. – Haoqing Value Stable No.8
margin business about top ten common
Investment Fund holds shares of the Company through margin trading and negotiable
stock shareholders with un-restrict
securities account that is 4,118,716 shares in total.
shares held (if applicable)
4. Changes of controlling shareholders or actual controller
Changes of controlling shareholders in reporting period
□ Applicable √ Not applicable
Changes of controlling shareholders had no change in reporting period.
Changes of actual controller in reporting period
□ Applicable √ Not applicable
Changes of actual controller in reporting period had no change in reporting period.
3
5. Total preferred stock shareholders of the Company and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
The Company had no shareholders with preferred stock held in the reporting.
6. Corporate bonds
Whether the Company has a corporation bonds that issuance publicly and listed on stock exchange and without due on the date when
semi-annual report approved for released or fail to cash in full on due
No
III. Discussion and analysis by the Management Team
1. Introduction of operation in the reporting period
Whether the Company needs to comply with the disclosure requirements of the particular industry
Reference disclosure
Retailing industry
In the first half of 2018, Sinopharm Accord focused on a clear development strategy and clear goals, transformed
both foreground and background, innovated together, and took serious measures to business landing, and made
steady growth in business performance, and showed potential in business models.
(i) Performance completion in first half of 2018
Sinopharm Accord achieved a revenue from operation amounted as 20.779 billion Yuan with a y-o-y growth
1.24%; the net profit attributable to parent Company comes to 642 million Yuan with 15.39% up on a y-o-y basis.
The pharmaceutical distribution has operation revenue of 15.879 billion Yuan with y-o-y growth of 0.79%; net
profit attributable to parent Company has 333 million Yuan with y-o-y growth of 8.93%. As for the
pharmaceutical retail, the Company gains 5.144 billion Yuan in operation revenue, a y-o-y growth of 5.23% and
the net profit attributable to parent Company amounted as 139 million Yuan, a 40.66% up on a y-o-y basis.
(ii) Analysis of policy environment
1. Industry growth rate continued to slow down, and the trend of leading concentration ratio remained unchanged
In the first quarter of 2018, the growth of drug distribution and sales increased by 7.9%, a decline of 0.5% on a
year-on-year basis; the growth of drug retail and sales increased by 9.1%, and an increase of 0.1% on a
year-on-year basis. The growth rate of large pharmaceutical wholesale enterprises slowed down noticeably, the
main business income of top 100 wholesale enterprises increased by 8.4% in 2017, a decline of 5.6% on a
year-on-year basis; the top 100 market share was 70.7%, a decline of 0.2% on a year-on-year basis; the market
share of 4 leading enterprises was 37.6%, a rise of 0.2 % on a year-on-year basis.
2. The total number of medical institutions was expanding, and the process of rational allocation of medical
resources was accelerating
Under the policy promoting, more than 19,000 new-level medical and health institutions have been added, and the
growth rate of the number of medical treatments and inpatient number has far exceeded that of class hospitals, and
the medical resources are constantly leaning toward the basic level.
4
(iii) The main work completed by the Company in the first half of 2018
1. Integrated wholesale and retail, and dug deep into resource advantages
During the reporting period, the Company’s catalogue management of wholesale and retail integration variety
increased from 33 brands to 77 brands, and the number of articles increased from 255 to 430. Through the
planning for wholesale and retail integration suppliers, seven suppliers were promoted to boost the wholesale and
retail integration project, at the same time, further promoted the wholesale and retail cooperation project of Guoda
Drugstore.
2. Implemented information technology projects, and strengthened new competence of technology
The Company attached great importance to the construction of IT talent team, increased recruitment efforts,
comprehensively strengthened the “informatization” orientation, and established a matching performance
incentive mechanism. During the reporting period, the Company optimized the basic management by information
technology, created a dual information platform of “Hospital Supply Chain Management” and “Retail Professional
Supply Chain Management”, and promoted the new business model through the integration of technology:
3. Organized the full docking with Walgreens Boots Alliance, and the projects were implemented smoothly
After many times of communication and combining the research on the market, the new term of board of directors
of the joint-ventured Guoda Drugstore reached a consensus on the strategic planning for the next 3-5 years and
formed specific strategic measures.
4. Distribution focused on four major directions, transformation and innovation for development
(1) Primary care:
The Company actively responded to the “two-vote system”, made overall plans, made variety planning, resource
docking and channel merging; improved the supply chain efficiency by building invoice management system,
procurement tax refund process optimization, multi-warehouse operation inventory management, etc.; in order to
meet the business needs, the Company established standardized prepayment and cash deposit operation
procedures to effectively control payment risks.
In response to the “GPO”, various regions and multiple channels actively proposed suggestions for the GPO
program, and signed strategic cooperation framework agreements with Taishan, HeYuan, Maoming and other
places; actively affected the variety catalogue of Foshan implementation plans, and strived to supplement the key
varieties, improved the maximum match between the varieties and the implementation catalog; the GPOs in
Shenzhen and Dongguan entered the implementation stage, and the Company maintained active communication
and responded well.
The Company directly faced the pharmacy custody at various regions, actively participated in the bidding of
various custody projects, strengthened the front-end business management, actively interpreted and responded to
the bidding work, formulated the bidding tools, and formed the standardization process of the universal template +
customized solution; and insisted on the individualized response in the hospitals in trust, integrated the varieties
and business resources, adjusted the cooperation models, and maintained the share and improved the gross profit.
(2) Retail diagnosis and treatment:
During the reporting period, there were 51 retail clinics, including 10 ones newly established in Guangdong and
5
two ones newly established in Guangxi in the first half of the year. Foshan Pharmacy and Foyi Pharmacy became
the specific pharmacies in Foshan City. Shenzhen Pharmacy and Zhaoqing Pharmacy won the first batch of
“Guangdong Provincial Demonstration Pharmacies”.
5. Guoda Drugstore ensured stock and made increment, and elaborately operated new features
(1) Accelerated the distribution speed according to strategic deployment
As of the end of the reporting period, the total number of Guoda Drugstore reached 4,004, and accumulatively had
a net increase of 169 stores in the first half of the year, including 163 direct-sale stores. The distribution points of
advantageous areas were scattered, strengthened the regional management, formulated the implementation plan of
the store transfer shop model, carried out help guidance on the spot, and grasped the local policies through
analysis and continued to follow up. Guoda Drugstore pre-judged the policy changes and market trends, and
increased the expansion speed of stores around hospitals. In the first half of the year, 29 new stores around
hospitals were added, and there were totally 332 stores around hospitals as of the end of the reporting period.
(2) Dug the potential benefits of stock stores and created specialized pharmacies with chronic diseases as the core
Optimized store management and managed the loss-making stores; established records and set up warehouses,
implemented chronic disease services and membership management
(3) Implemented the integration strategy of wholesale and retail, and strengthened the fine management of
merchandize purchase
Implemented the provincial-level platform construction of Guoda Drugstore step by step, docked the project of
wholesale and retail integration, implemented the strategic requirements, completed the docking with
manufacturers, and sought a new cooperation mode; carried through the fine management to merchandize
purchase and sales, promoted the application planning guidebook and tapped the potential in inter-regional
benchmarking; focused on the category inside, used the benchmarking method of same type of commodity to find
the superior goods, and increased the sales quota of superior goods.
(4) Accelerate the exploration of e-commerce business new model
Guoda Drugstore has negotiated cooperation with a number of internet hospitals and reached a nationwide
cooperation agreement with Yaofangyun. At present, the cooperation in Ningxia and Xiamen has already been
implemented.
2. Matters relevant to financial report
(1) Particulars about the changes in aspect of accounting policy, estimates and calculation method
compared with the accounting period of last year
√Applicable □ Not applicable
I. General description of change of accounting policies
1. The Ministry of Finance amended Business Accounting Standards No.14 - Revenue on 5 July 2017
(CK[2017]No.22).
6
2. The Ministry of Finance amended Business Accounting Standards No.22 - Recognition and measurement of
financial instrument (CK[2017]No.7), Business Accounting Standards No.23 - Transfer of financial assets
(CK[2017]No.8) and Business Accounting Standards No.24 - Hedging accounting (CK[2017]No.9) on 31
March 2017, and amended Business Accounting Standards No.37 - Presentation of financial instruments
(CK[2017]No.14) on 2 May 2017.
The above amended standards are applicable to those enterprises listed on both domestic and overseas securities
markets and to those enterprises listed on overseas securities market where the international financial reporting
standards or business accounting standards are adopted to prepare financial statements with effect from 1 January
2018.
II. Reasons for and dates of change of accounting policies
1. On 5 July 2017, the Ministry of Finance issued the amended Business Accounting Standards No.14 - Revenue,
which will be applicable for those enterprises listed on both domestic and overseas securities markets with effect
from 1 January 2018, while applicable to other domestic-listed enterprises since 1 January 2020.
2. On 31 March 2017, the Ministry of Finance issued the amended Business Accounting Standards No.22 -
Recognition and measurement of financial instrument, Business Accounting Standards No.23 - Transfer of
financial assets and Business Accounting Standards No.24 - Hedging accounting, and issued the amended
Business Accounting Standards No.37 - Presentation of financial instruments on 2 May 2017 (together referred to
as “New Series of Standards on Financial Instruments ”), which will be applicable for those enterprises listed on
both domestic and overseas securities markets with effect from 1 January 2018, while applicable to other
domestic-listed enterprises since 1 January 2019.
3. Due to that the parent of the Company is Sinopharm Group Co., Ltd. (“Sinopharm”) which is listed on overseas
market offering H shares, the Company begun to implement the above standards since 1 January 2018 so as to
keep the same accounting policies with Sinopharm.
III. Major changes in accounting policies and the influence upon the Company
(I)Change of accounting policy for revenue
1. Major changes of Business Accounting Standards No.14 - Revenue (CK[2017]No.22) are set out below:
(1)the current revenue and construction contract standards are incorporated into a unified revenue recognition
model;
(2)to replace the risk-and-reward approach with the transfer-of-control approach as the criteria for the time of
revenue recognition;
(3)to identify each single performance obligation included in a contract and recognize revenue separately when
7
performing the obligation;
(4)to provide a more prescriptive guidance including the accounting treatment of contract concerning multiple
trading arrangements;
(5)expressly formulates the revenue recognition and measurement of certain specific transactions (or matters).
2. Influence on the Company arising from this change
The Company will implement this new standard since 1 January 2018. According to the requirements during
transition of the old and new standards, a company shall adjust the opening retained earning and amounts of other
related items in the financial statements based on the accumulative affected amount upon initial implementation of
this standard, while make no adjustment to figures of comparative periods. Adopt of this standard will lead to
material change of revenue recognition method of the Company, and will not materially affect net profit, total
assets and net assets for the period and previous periods.
(II)Changes in accounting policies for financial instruments
1. Major changes of Business Accounting Standards No.22 - Recognition and measurement of financial
instrument, Business Accounting Standards No.23 - Transfer of financial assets, Business Accounting Standards
No.24 - Hedging accounting and Business Accounting Standards No.37 - Presentation of financial instruments are
set out below:
(1)the classification of financial assets shall be based on “business model” for possessing the financial assets and
“contractual cash flow characteristics of financial assets”, and financial assets shall be classified into three types,
namely, financial asset measured at amortized cost, financial asset measured at fair value through other
comprehensive income and financial asset measured at fair value through profit or loss;
(2)the accounting policy for provision for impairment loss of financial assets shall change from the approach of
“incurred loss” to “expected credit loss”, and the scope of provision is enlarged;
(3)with respect to non-trading equity instrument investment of financial assets at fair value through other
comprehensive income, the portion which is included in other comprehensive income in subsequent measurement
cannot be transferred to profit or loss for the period when being disposed, instead thereof, direct adjustment to
retained earning;.
(4)the determination principle and accounting treatment of transfer of financial assets are further clarified;
(5)with respect to hedge accounting, the qualified hedged projects and scope of hedge instruments are enlarged,
with qualitative hedge effectiveness test requirement replacing quantitative requirements; introduce hedge relation
“re-balance” system;
(6)the disclosure requirements for financial instruments shall be adjusted accordingly.
2 Influence on the Company arising from this change:
(1)Sinopharm Guoda Drugstore Co., Ltd., a subsidiary of the Company, holds shares in Shanghai Guoda
8
Shuguang Drugstore Co., Ltd., Shanghai Guoren Drugstore Co., Ltd., Sinopharm Hubei Guoda Drugstore Co.,
Ltd., Hunan Zhongbai Pharmacy Investment Co., Ltd. And Sinopharm Health Online Co., Ltd, with the voting
right of 25%, 10%, 10%, 6.31% and 8.06%, respectively. However, the directors and senior management of the
five companies are not appointed by the Group, and the Group has not participated or affected their financial and
operating decisions or normal operating activities in other means. Therefore, the Group exercises no significant
influence in the five companies, which makes the Group to calculate them as available-for-sale equity instruments
at carrying value.
After adoption of the new amended financial instruments related standards, the Company determines to designate
it as the financial asset at fair value through other comprehensive income after considering the contractual cash
flow characteristics and business model of the financial assets. These assets would be measured at fair value
through other comprehensive income in subsequent periods and would not be transferred to profit or loss in
subsequent periods. Upon derecognition of financial assets, the accumulative gains or losses previously recorded
in other comprehensive income will be transferred out from other comprehensive income and recorded in retained
earning. This change of financial instruments related accounting policies will not materially affect the opening
retained earning and other comprehensive income of the Company for 2018, no need to make retrospective
adjustments.
(2)Under the original financial instruments standards, the Company conducts check on carrying value of financial
assets on each balance sheet date, and provides for impairment provision when there is objective evidence
indicating the financial asset is impaired. Objective evidence indicating a financial asset is impaired refers to an
event that is actually occurred after initial recognition of the financial asset which affects the predicted future cash
flow of the asset and the affect can be measured reliably by the company. The new financial instruments standards
adopt expected credit loss to measure impairment. Under the new impairment measurement, the Company will
need to consider more expected loss risk. It shall recognize the “expected credit loss during the 12 months after
initial recognition” first, and recognize the “expected credit loss during the whole existence period” when the
credit loss increases significantly.
As for financial assets measured at amortized cost, such as receivables, the single financial asset with significant
amount is tested separately for impairment test and impairment provision is made based on the difference between
the present value of expected future cash flow less than the carrying value of the asset under the original standards;
the single financial asset not in significant amount and financial asset which is not impaired after separate test
shall make impairment test with incorporation into financial assets group with similar credit risk characteristics,
and impairment provision is made under aging analysis method. Based on the Company’s judgment, aging
analysis method may still be chosen to make impairment provision after adoption of the new financial instruments
standards, and it is expected that it will not bring significant influence on the financial statements.
9
This change of accounting policies brings no substantial influence on profit or loss, total assets and net assets of
the Company.
(2) Particulars about retroactive restatement on major correction for accounting errors in reporting period
□ Applicable √ Not applicable
There is no particular about retroactive restatement on major correction for accounting errors in reporting period
(3) Particulars about the change of consolidation range compared with the accounting report of last year
√ Applicable □ Not applicable
Changes of consolidation range found more in annotation VIII
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
24 August 2018
10
